Cycloset and Breastfeeding
Studies suggest that Cycloset does not pass through breast milk. It is generally recommended that breastfeeding women avoid taking Cycloset, however, as the drug can reduce breast milk production. Before taking Cycloset, women who are nursing should first consult their healthcare providers to discuss the benefits and potential risks.
Cycloset™ (bromocriptine mesylate) should not be used by breastfeeding women, as it suppresses lactation (breast milk production). Therefore, you should talk with your healthcare provider before taking it if you are breastfeeding or plan to start.
Limited information suggests that Cycloset probably does not pass through breast milk and probably does not cause any problems in breastfed infants. However, because Cycloset decreases the production of prolactin (a hormone that is essential for breastfeeding), it may decrease your milk production. At low doses, some women may be able to take Cycloset while breastfeeding.
At one point, bromocriptine (the active ingredient in Cycloset) was approved to suppress lactation after childbirth, typically for women who chose not to breastfeeding or could not breastfeed. For instance, it was sometimes used to suppress lactation in women after a stillbirth. However, the medication does have risks, and bromocriptine is no longer approved for this use. Strokes, heart attacks, seizures, and problems with blood pressure have been reported in women who used bromocriptine to suppress lactation, and the risks usually outweigh the possible benefits.
You should talk with your healthcare provider about breastfeeding while taking Cycloset. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.